About
Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease: Galimedix’s initial areas of focus.
Its amyloid beta-targeting approach is strongly supported by our license deal with a major ophthalmology player, as well as recent successes in the field of Alzheimer’s disease.
Galimedix’s approach blocks a key step in the neurodegenerative process with a highly specific, well tolerated small molecule without impacting normal neuronal function. This key step – the formation of toxic oligomers and protofibrils of amyloid beta (Aβ) – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals and by positive late-stage clinical results with Aβ-targeting therapies for Alzheimer’s disease, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.
Funding history · 1 round · $2.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Galimedix Therapeutics' primary focus in drug development?
- Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies for serious eye and brain diseases, specifically targeting conditions where amyloid beta plays a role, such as dry AMD, glaucoma, and Alzheimer's disease.
- When was Galimedix Therapeutics founded?
- Galimedix Therapeutics was founded in June 2017.
- What was the total amount raised by Galimedix Therapeutics in its funding rounds?
- Galimedix Therapeutics has raised a total of $2,000,000 in funding.
- Which investors participated in Galimedix Therapeutics' Seed round in January 2019?
- In January 2019, Galimedix Therapeutics completed a Seed round with participation from InFocus Capital Partners and Rimonci Capital.
- What new scientific data did Galimedix Therapeutics present in March 2024?
- In March 2024, Galimedix Therapeutics presented new scientific data at AD/PD™ 2024, demonstrating promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease.
- What was the significance of Biogen's Aducanumab Phase 3 results for Galimedix Therapeutics' GAL-101 in October 2019?
- In October 2019, positive Phase 3 results of Biogen's Aducanumab provided target validation for Galimedix Therapeutics' GAL-101.
- What did preclinical studies of GAL-101 demonstrate in May 2019?
- In May 2019, preclinical studies showed that Galimedix Therapeutics' investigational compound GAL-101 has a neuroprotective effect against toxic amyloid-beta in models of dry AMD and glaucoma.
- What leadership appointment did Galimedix Therapeutics make in December 2018?
- In December 2018, Galimedix Therapeutics appointed Hermann Russ, M.D., Ph.D., as its Chief Scientific Officer.